Douglas D. Taylor

Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles.

Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University.[1] Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky.[1] He was also on the faculty of the University of California, Davis.[2] From 2013–15, he was the Chief Scientific Officer of Aethlon Medical's wholly owned subsidiary, Exosome Sciences.[3][4]

Taylor first described exosomes in the 1980s, originally believing them to be cell fragments.[5] He later wrote that exosomes could potentially be used as biomarkers for profiling in ovarian cancer biopsies, and could extend their utility to screening other asymptomatic areas.[6]

In 2015, the Journal of Immunology retracted a paper it published in 2006 and which Taylor had co-written[7] after an "institutional research misconduct investigation committee determined that multiple figures in the...paper were falsified".[8][9] Taylor responded to the retraction on the blog Retraction Watch, disputing various aspects of the retraction, and stating that he sent "copies of the original data so that the [journal's] editor could independently verify that no falsification or fabrication occurred".[9]

References

  1. 1 2 "Aethlon Medical Appoints Douglas Taylor to Exosome Sciences Advisory Board". PR Newswire (Press release). Retrieved August 31, 2016.
  2. ↑ UC Davis Health System, Department of Public Affairs and Marketing. "UC Davis Health System Feature Story: Cancer in the crosshairs". ucdavis.edu. Retrieved 15 July 2015.
  3. ↑ "Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.". PR Newswire (Press release). Retrieved August 31, 2016.
  4. ↑ "Executive Team". Exosome Sciences. Archived from the original on August 17, 2015. Retrieved March 3, 2016.
  5. ↑ Todd S. Ing, et al, Dialysis: History, Development and Promise (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843
  6. ↑ Taylor, Douglas (July 2008). "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer". Gynecologic Oncology. 110 (1): 13–21. Retrieved 30 August 2016.
  7. ↑ "Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," Journal of Immunology, 2006 Feb 1;176(3):1534-42
  8. ↑ "Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," Journal of Immunology, June 15, 2015, vol. 194 no. 12 6190.(subscription required)
  9. 1 2 Bernès, Sylvain (June 10, 2015). "Exosome pioneer's paper retracted after investigation finds "multiple" faked figures". Retraction Watch. Retrieved January 7, 2016.
This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.